Skip navigation
Covered by Medicare for patients with muscle invasive bladder cancer

Signatera™ for Bladder Cancer

Personalized molecular residual disease (MRD) testing in bladder cancer

Helping to detect early signs of bladder cancer recurrence ahead of traditional imaging, identify patients who may benefit from additional treatment, and evaluate treatment response.1-3

Signatera is now covered by Medicare in muscle invasive bladder cancer

Patient and Doctor

What does residual disease detection offer?4

After a recurrence of bladder cancer, Bonnie and her doctor used Signatera to help monitor how well her immunotherapy treatment was working. Signatera testing helped guide important treatment change decisions and provided comfort to Bonnie.

“Getting the results of [Signatera] made me feel comfortable in enjoying life.” – Bonnie Miller

How is Signatera used in muscle invasive bladder cancer (MIBC)?

  • Signatera can help predict if disease is likely to recur without further treatment1
  • After cystectomy (surgery), Signatera can inform the likelihood of benefit from further treatment1 2
  • Signatera can help predict if the tumor is responding to immunotherapy treatment3
Bladder Cancer Graph

Custom-built technology

How it works

DNA from cells in your body – both tumor and normal – can be found in your blood.

How it works

Signatera uses the unique signature of the tumor to look for cancer DNA in your blood.

How it works

Next time you see your oncologist, ask if Signatera can help inform your care.

Comprehensive reports

Each time you get a Signatera blood draw, your doctor will receive a report that indicates whether circulating tumor DNA (ctDNA) was detected in your blood. The report will also track ctDNA dynamics over time. Your Signatera results should always be interpreted by your doctor.


Negative result

ctDNA not detected

  • You are more likely to remain cancer-free if you were diagnosed with early stage cancer.
  • If you have metastatic cancer, a negative result may mean your treatment was able to decrease the number of dividing cancer cells, decreasing tumor DNA to undetectable levels. This means the treatment may be effective.

Positive result

ctDNA detected

  • A positive result indicates that tumor DNA has been detected in your blood and means there is higher risk for your cancer returning if you were diagnosed with early-stage cancer. Your doctor may continue to monitor your ctDNA levels to assess the tumor’s response to treatment
Arrow up Arrow down

ctDNA changes over time3


  • ctDNA dynamics trending upwards may mean the cancer is growing or spreading.
  • ctDNA dynamics trending downwards may mean the cancer is shrinking or responding to treatment.

IMPORTANT: Results may change over time. A negative ctDNA result does not guarantee that ctDNA is not in your blood, or that it will never be detected in the future. Ongoing monitoring with Signatera during your cancer care—as directed by your doctor—can help inform decisions for your care

Access Personalized Testing

Medicare Coverage

  • Signatera™ is covered by Medicare for patients with muscle invasive bladder cancer.
  • We welcome all insurance plans. Please refer to our list of in-network plans that we participate with, or call your insurance provider.
  • We offer financial assistance programs for those who qualify.

More Information

  • Find answers to your questions about eligibility, results, ordering, and more
  • Don’t see your question? Contact us here.

Looking for more information?

Call Natera at 650-489-9050 or fill out our contact form.

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.


1Powles T, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595(7867):432-437.

2Christensen E, et al. Early Detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol. 2019;37(18):1547-1557.

3Bratman SV, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020;1(9):873-881.

4WBUR. New Cancer Blood Test Finds Evidence Of Recurrence In Some Patients Months Before Traditional Scans. Accessed June 2022.

icon-angle icon-bars icon-times